💥 Gate Square Event: #PostToWinCC 💥
Post original content on Gate Square related to Canton Network (CC) or its ongoing campaigns for a chance to share 3,334 CC rewards!
📅 Event Period:
Nov 10, 2025, 10:00 – Nov 17, 2025, 16:00 (UTC)
📌 Related Campaigns:
Launchpool: https://www.gate.com/announcements/article/48098
CandyDrop: https://www.gate.com/announcements/article/48092
Earn: https://www.gate.com/announcements/article/48119
📌 How to Participate:
1️⃣ Post original content about Canton (CC) or its campaigns on Gate Square.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostTo
Zuo Li Pharmaceutical: The development work of Ling Yi Bio's Parkinson's pipeline LY-N001 is ongoing.
Jin10 data reported on September 7th that Zoli Pharmaceutical stated during an institutional survey that the research and development of Lingyi Bio's Parkinson's pipeline LY-N001 is continuing to advance, with the main preclinical research work already completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of filing IND applications in China and the US and conducting clinical research as well as global market layout. Lingyi Bio is a company focused on the R&D of innovative drugs for single-gene genetic diseases, positioned to develop gene therapies with differentiated advantages. The company increased its investment in Lingyi Bio by 20 million yuan in April 2025.